Bitget App
Trade smarter
Buy cryptoMarketsTradeFuturesStocksEarnInstitutionAI & More
Why Is Candel Therapeutics Stock Falling Friday?

Why Is Candel Therapeutics Stock Falling Friday?

FinvizFinviz2026/02/20 10:57
By:Finviz

Candel Therapeutics, Inc. (NASDAQ:CADL) shares are down during Friday’s premarket session as the company announced the pricing of a public offering.

The stock’s decline follows news that Candel intends to use the proceeds from the offering to support critical launch readiness and ongoing development costs for its cancer therapies.

Equity Raise

Candel Therapeutics priced an underwritten public offering of around 18.35 million shares at $5.45 per share, aiming to raise approximately $100 million before expenses.

The offering is expected to close on or about February 23.

In addition to funding launch readiness for its lead product candidate, aglatimagene besadenovec (CAN-2409), the company will also allocate resources towards ongoing development costs related to its phase 3 trial in non-small cell lung cancer (NSCLC).

This strategic move highlights Candel’s commitment to advancing its pipeline of viral immunotherapies.

Lead Asset Overview

In an oral presentation at the 2025 ASTRO Annual Meeting, Candel Therapeutics presented subgroup analyses focused on the radiation regimen used during its phase 3 trial of CAN-2409 in patients with intermediate-to-high-risk localized prostate cancer.

CAN-2409 demonstrated statistically significant improvement in prostate cancer-specific disease-free survival (Hazard Ratio (HR) 0.62; p=0.0046). Effects were observed with both moderate hypo-fractionated and conventional external beam radiation therapy.

Technical Analysis

Currently, the stock is trading 10.4% below its 20-day and 50-day simple moving averages (SMA), indicating bearish momentum. Shares have decreased by 51.27% over the past 12 months and are positioned closer to their 52-week lows than highs.

The RSI is at 54.02, which is considered neutral territory, suggesting that the stock is neither overbought nor oversold. Meanwhile, the MACD shows a value of -0.0157, with the signal line at -0.0165, indicating a bullish crossover as the MACD is above the signal line.

The combination of neutral RSI and bullish MACD suggests mixed momentum, indicating that while the stock may not be in a strong trend, there is potential for upward movement.

  • Key Resistance: $5.50
  • Key Support: $5.00

Analyst Consensus & Recent Actions: The stock carries a Buy Rating with an average price target of $15.77. Recent analyst moves include:

  • Stephens & Co.: Overweight (Maintains Target to $15.00) (December 8, 2025)
  • Citigroup: Buy (Lowers Target to $24.00) (November 14, 2025)
  • Stephens & Co.: Initiated with Overweight (Target $15.00) (October 28, 2025)

CADL Price Action: Candel Therapeutics shares were down 11.43% at $5.27 during premarket trading on Friday.

Image via Shutterstock

0
0

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.
Trade now!

You may also like

Nasdaq evaporated over $4 trillion in a week! After the global stock market's "Black Friday," the market begins to anticipate an AI industry chain rebound after excessive declines.

The S&P 500 Index plunged by 3.70% on Friday to 6,910.39 points, falling for the seventh consecutive trading day. Alongside the Dow Jones Industrial Average, which dropped 1.93%, both indices pulled back more than 10% from their historic closing highs, confirming entry into a technical correction. The Nasdaq Composite Index fell 5.28%, erasing its gains for the year. The Nasdaq 100 Index dropped 5.61%, falling about 19.84% from its historic closing high on October 6. At one point during the session, the decline exceeded 20%, entering what is referred to as a "technical bear market area."

智通财经•2026/11/21 02:01

VIX surges to highest level since the tariff dispute in April last year; Goldman Sachs Fear Index approaches maximum; US stocks may face another $80 billion sell-off next week

As the U.S. stock market faced a sharp sell-off on Friday, two major Wall Street market risk indicators issued warnings simultaneously.

智通财经•2026/11/20 23:42

Nvidia (NVDA.US) plunges 46% over seven weeks, marking the longest losing streak since the 2008 financial crisis, with its market capitalization evaporating by $2.6 trillion.

Nvidia is experiencing its longest consecutive weekly decline since the 2008 global financial crisis.

智通财经•2026/11/20 23:36

Overnight U.S. Stocks | Stocks, Gold, and Bitcoin Plunge Indiscriminately as VIX Fear Index Surges to 40, Nasdaq Wipes Out Year-to-Date Gains

At the close, the Dow Jones Industrial Average fell 949.73 points, or 1.93%, to 48,147.32 points; the S&P 500 index dropped 265.44 points, or 3.70%, to 6,910.39 points; and the Nasdaq declined 1,261.46 points, or 5.28%, to 22,617.73 points, down 2.7% year-to-date.

智通财经•2026/11/20 23:31